Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Department of Nuclear Medicine, Charité Berlin, Berlin, Germany.
Nutr Cancer. 2025;77(1):102-114. doi: 10.1080/01635581.2024.2401648. Epub 2024 Sep 22.
The purpose of the meta-analysis was to compare the prevalence of sarcopenia on staging computed tomography (CT) in patients with solid tumors in different world regions. MEDLINE, Embase, and SCOPUS literature databases were screened for prevalence of sarcopenia in oncologic patients up to December 2022. Two hundred eighty studies met the inclusion criteria. The methodological quality of the involved studies was checked according to the Quality Assessment of Diagnostic Studies instrument. Two hundred eighty studies with 81,885 patients were included. The prevalence of sarcopenia among all patients was 35.5%. Prevalence of sarcopenia was higher in Europe (45.6%) and North America (41.2%) than in Asia (29.6%). Prevalence rates for the curative cohort were similar in all three regions, with 43.7% in Europe, 41.3% in North America, and 37.4% in Asia. In the palliative cohort, sarcopenia prevalence was higher in Europe (55.7%) and Asia (45.7%) than in North America (34.0%). In the European cohort, prostate cancer (73.9%), esophageal cancer (74.2%), pancreatic cancer (62.5%), and renal cell cancer (65.3%) showed high prevalence rates of sarcopenia. Applied cutoff values differed among regions. Our study shows that prevalence rates for sarcopenia of patients with solid tumors differ between regions and are different for curative and palliative settings. European studies demonstrate high prevalence rates for both settings. There is need for regional harmonization of sarcopenia definitions.
本荟萃分析的目的是比较不同世界区域实体瘤患者在分期计算机断层扫描（CT）中肌少症的患病率。截至 2022 年 12 月，我们筛选了 MEDLINE、Embase 和 SCOPUS 文献数据库中关于肿瘤患者肌少症患病率的研究。有 280 项研究符合纳入标准。根据诊断研究质量评估工具，检查了纳入研究的方法学质量。共纳入 280 项研究，涉及 81885 例患者。所有患者的肌少症患病率为 35.5%。欧洲（45.6%）和北美（41.2%）的肌少症患病率高于亚洲（29.6%）。三个地区的根治性队列的患病率相似，欧洲为 43.7%，北美为 41.3%，亚洲为 37.4%。在姑息性队列中，欧洲（55.7%）和亚洲（45.7%）的肌少症患病率高于北美（34.0%）。在欧洲队列中，前列腺癌（73.9%）、食管癌（74.2%）、胰腺癌（62.5%）和肾细胞癌（65.3%）显示出较高的肌少症患病率。应用的截断值在不同地区有所不同。我们的研究表明，实体瘤患者肌少症的患病率在不同地区存在差异，且在根治性和姑息性治疗中存在差异。欧洲的研究显示这两种情况的患病率都很高。需要对肌少症的定义进行区域协调。
